1. 1) Iesalnieks I, Rümmele P, Dietmaier W, Jantsch T, Zülke C, Schlitt HJ, et al. Factors associated with disease progression in patients with gastrointestinal stromal tumors in the pre-imatinib era. Am J Clin Pathol. 2005 Nov;124(5):740–748.
2. 2) Yokoi K, Tanaka N, Shoji K, Ishikawa N, Seya T, Horiba K, et al. A study of histopathological assessment criteria for assessing malignancy of gastrointestinal stromal tumor, from a clinical standpoint. J Gastroenterol. 2005 May;40(5):467–473.
3. 3) Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004 Jul;28(7):889–894.
4. A Huge Duodenal Gastrointestinal Stromal Tumor Penetrating to the Duodenal Lumen after Administration of Imatinib Mesylate